Review Article on Unresolved Issues in Pancreatic Cancer1
Artificial intelligence and imaging for risk prediction of pancreatic cancer: a narrative review
Chinese Clinical Oncology
2022;
11
(1)
:1
.
(28 February 2022)
Upfront surgery vs. neoadjuvant therapy for resectable pancreatic cancer: a narrative review of available evidence
Chinese Clinical Oncology
2022;
11
(1)
:2
.
(28 February 2022)
Minimally invasive surgery for pancreatic cancer—are we there yet?—a narrative review
Chinese Clinical Oncology
2022;
11
(1)
:3
.
(28 February 2022)
Immunotherapy in pancreatic cancer—an emerging role: a narrative review
Chinese Clinical Oncology
2022;
11
(1)
:4
.
(28 February 2022)
Genetic landscape of pancreatic cancer: a narrative review
Chinese Clinical Oncology
2022;
11
(1)
:5
.
(28 February 2022)
“Mitigation strategies for post-operative pancreatic fistula after pancreaticoduodenectomy in high-risk pancreas: an evidence-based algorithmic approach”—a narrative review
Chinese Clinical Oncology
2022;
11
(1)
:6
.
(28 February 2022)
Original Article
Assessing surrogacy using restricted mean survival time ratio for overall survival in non-small cell lung cancer immunotherapy studies
Chinese Clinical Oncology
2022;
11
(1)
:7
.
(28 February 2022)
Case Report
Neoadjuvant treatment of pancreatic carcinosarcoma: a case report and review of literature
Chinese Clinical Oncology
2022;
11
(1)
:8
.
(28 February 2022)
Disclosure:
1. The series “Unresolved issues in Pancreatic Cancer” was commissioned by the Editorial office, Chinese Clinical Oncology without any sponsorship or funding. Dr. Savio George Barreto served as the unpaid Guest Editor for the series.
